{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:25:12Z","timestamp":1789140312482,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00347971"],"award-info":[{"award-number":["RS-2024-00347971"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2025-02613113"],"award-info":[{"award-number":["RS-2025-02613113"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008003","name":"Korea Institute of Radiological and Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","award":["50531-2026"],"award-info":[{"award-number":["50531-2026"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bbrc.2025.153093","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:27:58Z","timestamp":1764808078000},"page":"153093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dual PI3K\u03b4\/\u03b3 inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS\u2013STING\u2013type I interferon signaling"],"prefix":"10.1016","volume":"795","author":[{"given":"Ye-Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-4515","authenticated-orcid":false,"given":"Jae-Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2025.153093_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib2","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fphar.2018.00522","article-title":"Ionizing radiation-induced cellular senescence in normal, non-transformed cells and the involved DNA damage response: a mini review","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2025.153093_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2025.153093_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228877","article-title":"The impact of radiation-induced DNA damage on cGAS-STING-Mediated immune responses to cancer","volume":"21","author":"Storozynsky","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2025.153093_bib6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-024-05191-6","article-title":"cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors","volume":"81","author":"Li","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbrc.2025.153093_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.ijrobp.2010.09.034","article-title":"Radiation enhances regulatory T cell representation","volume":"81","author":"Kachikwu","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbrc.2025.153093_bib8","doi-asserted-by":"crossref","first-page":"5679","DOI":"10.1158\/0008-5472.CAN-09-4446","article-title":"Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation","volume":"70","author":"Kozin","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153093_bib9","first-page":"3276","article-title":"Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications","volume":"5","author":"Liu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153093_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.trsl.2017.11.002","article-title":"The role of macrophage phenotype in regulating the response to radiation therapy","volume":"191","author":"Shi","year":"2018","journal-title":"Transl. Res."},{"key":"10.1016\/j.bbrc.2025.153093_bib11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41401-020-00500-8","article-title":"Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2025.153093_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153093_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153093_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2025.153093_bib16","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood.2021011597","article-title":"PI3Kdelta\/gamma inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity","volume":"139","author":"Funk","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2025.153093_bib17","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1158\/0008-5472.CAN-16-2534","article-title":"Anti-PD-L1 efficacy can be enhanced by inhibition of Myeloid-Derived suppressor cells with a selective inhibitor of PI3Kdelta\/gamma","volume":"77","author":"Davis","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153093_bib18","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejca.2021.08.029","article-title":"PI3Kgammadelta inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model","volume":"157","author":"Han","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003762","article-title":"PI3Kdelta\/gamma inhibitor BR101801 extrinsically potentiates effector CD8(+) T cell-dependent antitumor immunity and abscopal effect after local irradiation","volume":"10","author":"Yoon","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib20","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1186\/s12885-023-11742-0","article-title":"Endosulfine alpha maintains spindle pole integrity by recruiting Aurora A during mitosis","volume":"23","author":"Kim","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2025.153093_bib22","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajh.25243","article-title":"Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study","volume":"93","author":"O'Brien","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2025.153093_bib23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.153093_bib24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2025.153093_bib25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110delta Isoform inhibitor Idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbrc.2025.153093_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","article-title":"Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2025.153093_bib27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2025.153093_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fimmu.2019.00193","article-title":"Role of radiation therapy in modulation of the tumor stroma and microenvironment","volume":"10","author":"Menon","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2025.153093_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12185-023-03689-6","article-title":"Japanese phase Ib study of the oral PI3K-delta and -gamma inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"119","author":"Makita","year":"2024","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bbrc.2025.153093_bib30","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.3324\/haematol.2024.285043","article-title":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","volume":"109","author":"Danilov","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.bbrc.2025.153093_bib31","unstructured":"L. Boryung Pharmaceutical Co., BR101801: Clinical Study Record Detail, n.d."},{"key":"10.1016\/j.bbrc.2025.153093_bib32","unstructured":"N.I.o. Health, Studies found for: BR101801, https:\/\/clinicaltrials.gov\/study\/NCT04018248, n.d."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25018091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:04:22Z","timestamp":1781323462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25018091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"alternative-id":["S0006291X25018091"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153093","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual PI3K\u03b4\/\u03b3 inhibition enhances radiotherapy-induced antitumor immunity via macrophage-dependent cGAS\u2013STING\u2013type I interferon signaling","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153093"}}